title: Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer?
authors.forename: J
authors.initials: J
authors.lastname: Trojan
authors.forename: M
authors.initials: M
authors.lastname: Stuermer
authors.forename: G
authors.initials: G
authors.lastname: Teuber
authors.forename: A
authors.initials: A
authors.lastname: Berger
authors.forename: D
authors.initials: D
authors.lastname: Faust
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D024921:Drug Resistance, Multiple, Viral; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D000068698:Tenofovir
chemical_list: D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D000068698:Tenofovir; D000225:Adenine; C106812:adefovir dipivoxil